LAIYANG, China, Jan. 12 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (the "Company" or "Jiangbo"), a pharmaceutical company with its principal operations in China, today announced that one of its factories in China obtained a renewal of its Good Manufacturing Practices Certificate for Pharmaceutical Products ("GMP Certificate") from the State Food and Drug Administration (SFDA) for its tablets and granules. The new certificate will be valid until November 2014. Jiangbo has another GMP certified factory to produce Traditional Chinese medicines in tablets, granules, pills, mixture, syrup, and concentrated decoction.
According to the National Medicine Administration Law of the People's Republic of China, all pharmaceutical manufacturers are required to pass an examination every five years to renew their GMP Certificates. In November 2009, the examination committee visited the Company and conducted a review of its supply chain management practices, including quality control of raw materials, its manufacturing processes, and the inspection and acceptance of its finished products.
"We are pleased to obtain the renewal of our GMP Certificate, which reinforces Jiangbo's commitment to providing the highest quality pharmaceutical products to patients," said Mr. Wubo Cao, the Company's Chief Executive Officer.
About Jiangbo Pharmaceuticals, Inc.
Jiangbo Pharmaceuticals is engaged in the research, development, production, marketing and sales of pharmaceutical products in China. The Company's operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong Province. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. For additional information, please visit the Company's website (http://www.jiangbopharma.com ).
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
CONTACT: Ms. Elsa Sung, CFO of Jiangbo Pharmaceuticals, Inc.,
+1-954-727-8435, email@example.com; Investor Relations Contact: Crocker
Coulson, President of CCG Investor Relations, firstname.lastname@example.org,
+1-646-213-1915 (NY office)
Web site: http://www.jiangbopharma.com//